DelveInsight’s analysis indicates that the Horner’s Syndrome pipeline involves over three key companies actively developing more than three treatment therapies for the condition.
Horner’s Syndrome Overview:
Horner’s Syndrome (CRPS) is a chronic pain disorder that usually develops following limb trauma and can affect one or multiple limbs. It is categorized into Type I, where nerve damage is not confirmed, and Type II, where there is verified nerve injury. CRPS is recognized as a regional post-traumatic neuropathic pain condition, with symptoms often disproportionately severe relative to the initial injury. The condition affects roughly 26 per 100,000 individuals, occurs more frequently in women (ratio 3.5:1), and is most common in people in their mid-thirties.
CRPS can result from various injuries, including fractures, sprains, crush injuries, nerve trauma, strokes, or surgical procedures, with about 91% of cases developing after surgery. The wrist is particularly susceptible, especially following distal radial fractures. While the exact cause is not fully understood, it is believed that immune system dysfunction may trigger nerve inflammation, impacting blood flow, sensation, and temperature regulation in the affected limb.
There is no definitive diagnostic test for CRPS; diagnosis is largely clinical and guided by the Budapest Criteria. Additional imaging, such as bone scans, X-rays, MRI, or specialized nerve studies, can help evaluate bone or nerve abnormalities. Although a cure is not currently available, early diagnosis and intervention are essential to managing symptoms, slowing disease progression, and enhancing quality of life.
Request for a detailed insights report on Horner’s Syndrome pipeline insights
“Horner’s Syndrome Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Horner’s Syndrome Therapeutics Market.
Key Takeaways from the Horner’s Syndrome Pipeline Report
-
DelveInsight’s Horner’s Syndrome pipeline report highlights an active and growing landscape, with more than three companies developing over three pipeline therapies for the treatment of Horner’s Syndrome.
-
Key companies in this space, including Takeda, Tryp Therapeutics, Soin Therapeutics, and others, are exploring innovative therapies to enhance the treatment options available for patients. Promising candidates in various stages of development include Soticlestat, TRP-8803, and additional drugs.
-
In March 2025, the North Queensland Persistent Pain Management Service was inaugurated at Townsville University Hospital. This $4.4 million facility provides comprehensive care for chronic pain conditions, including CRPS, with services offered both in-person and through telehealth.
-
In December 2025, the U.S. Food and Drug Administration granted Orphan Drug Designation to BRC-002, a novel oral cannabinoid therapy developed by Biopharmaceutical Research Company (BRC). BRC-002 is designed to target both the pain and associated comorbidities of CRPS, such as depression, anxiety, and sleep disorders. Its safety and efficacy are currently being assessed in an investigator-initiated Phase 1 clinical trial, with a Phase 2 study planned to begin by the end of 2025.
Horner’s Syndrome Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Horner’s Syndrome Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Horner’s Syndrome treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Horner’s Syndrome market.
Download our free sample page report on Horner’s Syndrome pipeline insights
Horner’s Syndrome Emerging Drugs
-
Soticlestat: Takeda
-
TRP-8803: Tryp Therapeutics
Horner’s Syndrome Companies
Approximately three or more leading companies are actively working on therapies for Horner’s Syndrome (CRPS), with Takeda having the most advanced candidates, currently in Phase II clinical trials.
DelveInsight’s report covers around 3+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Horner’s Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Horner’s Syndrome Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Horner’s Syndrome Therapies and Key Companies: Horner’s Syndrome Clinical Trials and advancements
Horner’s Syndrome Pipeline Therapeutic Assessment
• Horner’s Syndrome Assessment by Product Type
• Horner’s Syndrome By Stage
• Horner’s Syndrome Assessment by Route of Administration
• Horner’s Syndrome Assessment by Molecule Type
Download Horner’s Syndrome Sample report to know in detail about the Horner’s Syndrome treatment market @ Horner’s Syndrome Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Horner’s Syndrome Current Treatment Patterns
4. Horner’s Syndrome – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Horner’s Syndrome Late-Stage Products (Phase-III)
7. Horner’s Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Horner’s Syndrome Discontinued Products
13. Horner’s Syndrome Product Profiles
14. Horner’s Syndrome Key Companies
15. Horner’s Syndrome Key Products
16. Dormant and Discontinued Products
17. Horner’s Syndrome Unmet Needs
18. Horner’s Syndrome Future Perspectives
19. Horner’s Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Horner’s Syndrome Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/